Document is current
Any future updates will be listed below
-
Authors
Tanoue, Takeshi https://orcid.org/0000-0003-3639-8834
Nagayama, Manabu https://orcid.org/0000-0003-4088-2944
Roochana, Ayumi J. A.
Zimmerman, Samuel
Ashenberg, Orr
Jain, Tanvi
Igarashi, Ryo
Sasajima, Satoshi
Takeshita, Kozue
Hetherington, Nicola
Okahashi, Nobuyuki
Ueda, Masahiro
Konishi, Morichika https://orcid.org/0000-0002-2424-7169
Nakayama, Yoshiaki
Minoda, Aki
Skelly, Ashwin N. https://orcid.org/0000-0002-1565-3376
Minokoshi, Yasuhiko https://orcid.org/0000-0002-7119-4805
Pucci, Nicholas https://orcid.org/0009-0002-2668-6330
Mende, Daniel R.
Arita, Makoto https://orcid.org/0000-0001-9902-0463
Yamamoto, Hironori
Watanabe, Shunji
Miura, Kouichi
Behie, Scott W.
Suda, Wataru https://orcid.org/0000-0002-2861-9724
Sato, Toshiro https://orcid.org/0000-0001-8353-8137
Atarashi, Koji https://orcid.org/0000-0001-5422-0736
Matsushita, Mami
Kajimura, Shingo https://orcid.org/0000-0003-0672-5910
Plichta, Damian R. https://orcid.org/0000-0002-6555-2557
Saito, Masayuki
Xavier, Ramnik J. https://orcid.org/0000-0002-5630-5167
Honda, Kenya https://orcid.org/0000-0001-8937-9835
- License Information
-
More Information
Article History
Received: 14 November 2024
Accepted: 28 January 2026
First Online: 4 March 2026
Competing interests
: K.H. is a scientific advisory board member of Vedanta Biosciences, 4BIO Capital and Taxa. M.U. is an employee of JSR Corporation. R.J.X. is a co-founder of Jnana Therapeutics and Celsius Therapeutics, scientific advisory board member at Nestlé and board director at MoonLake Immunotherapeutics. D.R.P. is an employee of Novonesis. The remaining authors declare no competing interests.
